Trials suggest that fondaparinux reduces extension and recurrence of superficial venous thrombosis as well as progression to symptomatic embolism .
Fondaparinux is a factor Xa inhibitor .
Trials suggest that fondaparinux , a factor Xa inhibitor , reduces extension and recurrence of superficial venous thrombosis as well as progression to symptomatic embolism .